Luxturna (voretigene neparvovec or voretigene neparvovec-rzyl) is a type of gene therapy used to treat retinal dystrophy. This is a rare condition caused by a change in the RPE65 gene and can lead to blindess. Luxturna (voretigene neparvovec) is given as a single dose by surgical injection into each eye by a healthcare provider who is trained to perform eye surgeries. Side effects include eye redness and cataracts.
Some people with retinal dystrophy have changes in the RPE65 genes, and this can lead to vision loss and blindness.
Luxturna (voretigene neparvovec) is a type of gene therapy. It works by delivering working copies of the RPE65 gene into the eye. The eye is then able to make the proteins needed for healthy vision.
The following side effects may get better over time as your body gets used to the medication. Let your healthcare provider know immediately if you continue to experience these symptoms or if they worsen over time.
Contact your healthcare provider immediately if you experience any of the following.
Side effects that you should report to your care team as soon as possible:
Side effects that usually do not require medical attention (report these to your care team if they continue or are bothersome):
People in clinical studies for Luxturna (voretigene neparvovec) were given a vision test called the Multi-Luminance Mobility Test (MLMT). This test used an obstacle course with different levels of light to simulate everyday, real-world scenarios and environments, such as being in a well-lit room or walking around in a city at night. Studies show that one year after treatment, most people who received Luxturna (voretigene neparvovec) had improved vision and were able to complete the test at the lowest level of light.
Studies show that vision improved by 1 month after people were treated with Luxturna (voretigene neparvovec). This improvement in vision lasted for at least 4 years.
Luxturna (voretigene neparvovec) is given by a trained healthcare professional as an injection under the retina, which is the innermost layer of the eye. One eye is treated with Luxturna (voretigene neparvovec) at a time; both injections are typically separated by at least 6 days.
Luxturna (voretigene neparvovec) is made by Spark Therapeutics.
Luxturna (voretigene neparvovec) was approved by the FDA in 2017 as the first gene therapy for people with retinal dystrophy due to an abnormal RPE65 gene.
Luxturna (voretigene neparvovec) can cause some serious health issues. This risk may be even higher for certain groups. If this worries you, talk to your doctor or pharmacist about other options.
With any surgical procedure on the eye or injection into the eye, including treatment with Luxturna (voretigene neparvovec), there's a potential risk of an eye infection. Let your provider know right away if you experience any swelling or signs of an eye infection, such as new floaters, eye pain, or vision changes.
Receiving Luxturna (voretigene neparvovec) can lead to vision problems, including vision loss, due to damage to certain parts of your eye, such as the retina. These vision problems can happen due to a tear in the area of the injection, thinning of the retina, separation of retinal layers, or bleeding in the retina. Let your provider know right away if you have any changes to your eyesight, and report any signs of blurry vision, flashes of light, or floaters.
The Luxturna (voretigene neparvovec) injection can raise the pressure in your eye, which can lead to problems like vision loss or glaucoma if not caught and treated in time. Make sure to see your eye provider regular so your eyes can be examined. Your provider will monitor the pressure in your eye during your follow-up appointments.
An air bubble might form in the eye and stay there for a week or more after the Luxturna (voretigene neparvovec) injection. During this time, avoid any changes in altitude, such as flying, traveling to high-elevation places, or scuba diving. These activities can cause permanent vision loss if they're done while the air bubble is still in your eye. Your provider can check to see if the air bubble has disappeared before you travel or carry out these activities.
Treatment with Luxturna (voretigene neparvovec) is associated with a higher risk of developing cataracts. It can also make cataracts that you already have worse. Let your provider know if you develop blurry or cloudy vision.
A single dose of Luxturna (voretigene neparvovec) contains 1.5 x 1011 vector genomes (vg).
Your provider will inject one dose of Luxturna (voretigene neparvovec) beneath the retina of one eye at a special treatment clinic. Then, they'll inject the medication into the other eye at least 6 days later.